

CLAIMS

1. A pharmaceutical composition for prevention or treatment of diseases caused by interleukin-6 production, comprising an antibody to interleukin-6 receptor.

5 2. A pharmaceutical composition for prevention or treatment according to claim 1, wherein the disease caused by said interleukin-6 production is plasmacytosis.

10 3. A pharmaceutical composition for prevention or treatment according to claim 1, wherein the disease caused by said interleukin-6 production is hyperimmunoglobulinemia.

4. A pharmaceutical composition for prevention or treatment according to claim 1, wherein the disease caused by said interleukin-6 production is anemia.

15 5. A pharmaceutical composition for prevention or treatment according to claim 1, wherein the disease caused by said interleukin-6 production is nephritis.

20 6. A pharmaceutical composition for prevention or treatment according to claim 1, wherein the disease caused by said interleukin-6 production is cachexia.

7. A pharmaceutical composition for prevention or treatment according to claim 2, wherein said plasmacytosis is induced by rheumatism.

25 8. A pharmaceutical composition for prevention or treatment according to claim 2, wherein said plasmacytosis is induced by Castleman's disease.

9. A pharmaceutical composition for prevention or treatment according to claim 5, wherein said nephritis is mesangium proliferative nephritis.

30 10. A pharmaceutical composition for prevention or treatment according to ~~any of claims 1 to 9~~, wherein said antibody is a monoclonal antibody.

35 11. A pharmaceutical composition for prevention or treatment according to claim 10, wherein said antibody is PM-1 antibody.

12. A pharmaceutical composition for prevention or treatment according to claim 10, wherein said antibody is

08817507 041797

a chimeric antibody.

13. A pharmaceutical composition for prevention or treatment according to claim 10, wherein said antibody is a reshaped human antibody.

5 14. A pharmaceutical composition for prevention or treatment according to claim 13, wherein said antibody is a reshaped human PM-1 antibody.

ndd
B3

008150 0449
6/140 05/1880